{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:03:44Z","timestamp":1793736224372,"version":"4.6.1"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015834","name":"Ono Pharma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015834","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 vaccination or infection may not protect from future novel coronavirus outbreaks. Although several drugs targeting essential coronavirus proteins are broadly effective, the error-prone coronavirus RNA-dependent RNA polymerase and a rapid viral replication cycle mean that drug resistance will likely emerge. Small molecules that target sequence-stable host proteins could offer more durable pan-coronavirus activity. Here, we show that the well-tolerated and orally bioavailable small molecule SH-BC-893 protects from endosomal, but not plasma membrane, entry by diverse coronavirus strains. SH-BC-893 alters endolysosomal trafficking similar to PIKfyve inhibitors and, like hydroxychloroquine, reduces cathepsin L activity. While all three compounds block endosomal entry mediated by coronavirus spike proteins in vitro, PIKfyve inhibitors and chloroquine derivatives are ineffective or even increase viral titer in vivo. In contrast, SH-BC-893 reduced viral titer in the lungs of mice infected intranasally with the LD50 of the MHV-1 coronavirus by 3 logs. Thus, poor in vivo outcomes when using apilimod or chloroquine as anti-virals likely reflect pharmacologic limitations of these compounds rather than a flawed therapeutic strategy. We anticipate that SH-BC-893 or optimized analogs with similar tissue pharmacology could control infections by novel coronaviruses, particularly if given in combination with TMPRSS2 inhibitors to block entry at the plasma membrane, an obvious escape pathway. Because it targets host rather than viral proteins, SH-BC-893 might also block infection by many other viruses that enter via endosomal pathways: orthomyxoviruses (influenza), filoviruses (Ebola, Marburg), flaviviruses (Dengue, Zika, and West Nile), alphaviruses (Chikungunya) rhabdoviruses (rabies), and bunyaviruses (Hantaan or Sin Nombre). In sum, further evaluation of SH-BC-893 and\/or optimized analogs as potential pan-antiviral agents is merited.<\/jats:p>","DOI":"10.1038\/s41598-026-51335-y","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:12:15Z","timestamp":1778501535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Endolysosomal trafficking regulator SH-BC-893 inhibits coronavirus entry in vitro and in vivo"],"prefix":"10.1038","volume":"16","author":[{"given":"Brendan T.","family":"Finicle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle S.","family":"Perrochon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Buchmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee L.","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"51335_CR1","unstructured":"World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. (2015). https:\/\/www.who.int\/publications\/m\/item\/summary-of-probable-sars-cases-with-onset-of-illness-from-1-november-2002-to-31-july-2003"},{"key":"51335_CR2","first-page":"102","volume":"51","author":"S Alsolamy","year":"2015","unstructured":"Alsolamy, S. & Arabi, Y. M. Infection with Middle East respiratory syndrome coronavirus. Can. J. Respir. Ther. 51, 102 (2015).","journal-title":"Can. J. Respir. Ther."},{"key":"51335_CR3","unstructured":"World Health Organization. WHO EMRO | MERS outbreaks | MERS-CoV | Health topics. (2025). https:\/\/www.emro.who.int\/health-topics\/mers-cov\/mers-outbreaks.html"},{"key":"51335_CR4","unstructured":"World Health Organization. COVID-19 deaths | WHO COVID-19 dashboard. (2025). https:\/\/data.who.int\/dashboards\/covid19\/deaths"},{"key":"51335_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84138-0","volume":"15","author":"N Suntronwong","year":"2025","unstructured":"Suntronwong, N. et al. Neutralization of Omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated Omicron non JN.1 or JN.1 infections. Sci. Rep. 15, 1454 (2025).","journal-title":"Sci. Rep."},{"key":"51335_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2025.100664","volume":"24","author":"K Adhikari","year":"2025","unstructured":"Adhikari, K. & Verma, S. C. Neutralizing antibody responses to SARS-CoV-2 variants after COVID-19 vaccination and boosters. Vaccine X 24, 100664 (2025).","journal-title":"Vaccine X"},{"key":"51335_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2002083","volume":"18","author":"R Patel","year":"2022","unstructured":"Patel, R., Kaki, M., Potluri, V. S., Kahar, P. & Khanna, D. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum. Vaccin. Immunother. 18, 2002083 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"51335_CR8","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.immuni.2022.09.006","volume":"55","author":"S DeWolf","year":"2022","unstructured":"DeWolf, S. et al. SARS-CoV-2 in immunocompromised individuals. Immunity 55, 1779\u20131798 (2022).","journal-title":"Immunity"},{"key":"51335_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.1259","volume":"12","author":"J Bytyci","year":"2024","unstructured":"Bytyci, J., Ying, Y. & Lee, L. Y. W. Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: A systematic review. Immun. Inflamm. Dis. 12, e1259 (2024).","journal-title":"Immun. Inflamm. Dis."},{"key":"51335_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004493","volume":"22","author":"A Bhatia","year":"2025","unstructured":"Bhatia, A. et al. Effect of Nirmatrelvir\/Ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C. PLoS Med. 22, e1004493 (2025).","journal-title":"PLoS Med."},{"key":"51335_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40121-023-00760-x","volume":"12","author":"C Weng","year":"2023","unstructured":"Weng, C. et al. Safety and efficacy of Paxlovid against Omicron variants of coronavirus disease 2019 in elderly patients. Infect. Dis. Ther. 12, 649\u2013662 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"51335_CR12","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e211","volume":"38","author":"JM Kim","year":"2023","unstructured":"Kim, J. M., Yoo, M.-G., Bae, S. J., Kim, J. & Lee, H. Effectiveness of Paxlovid, an oral antiviral drug, against the Omicron BA.5 variant in Korea: Severe progression and death between July and November 2022. J. Korean Med. Sci. 38, e211 (2023).","journal-title":"J. Korean Med. Sci."},{"key":"51335_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-023-00900-3","volume":"13","author":"PO Godwin","year":"2024","unstructured":"Godwin, P. O., Polsonetti, B., Caron, M. F. & Oppelt, T. F. Remdesivir for the treatment of COVID-19: A narrative review. Infect. Dis. Ther. 13, 1\u201319 (2024).","journal-title":"Infect. Dis. Ther."},{"key":"51335_CR14","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1093\/cid\/ciad460","volume":"77","author":"E Mozaffari","year":"2023","unstructured":"Mozaffari, E. et al. Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: Findings from routine clinical practice. Clin. Infect. Dis. 77, 1626\u20131634 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"51335_CR15","doi-asserted-by":"publisher","first-page":"6771","DOI":"10.1073\/pnas.1922083117","volume":"117","author":"E de Wit","year":"2020","unstructured":"de Wit, E. et al. Prophylactic and therapeutic Remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc. Natl. Acad. Sci. U.S.A. 117, 6771\u20136776 (2020).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"51335_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren, T. K. et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531, 381\u2013385 (2016).","journal-title":"Nature"},{"key":"51335_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22132-0","volume":"12","author":"RW Cross","year":"2021","unstructured":"Cross, R. W. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat. Commun. 12, 1891 (2021).","journal-title":"Nat. Commun."},{"key":"51335_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000544","volume":"2","author":"L Rong","year":"2010","unstructured":"Rong, L., Dahari, H., Ribeiro, R. M. & Perelson, A. S. Rapid emergence of protease inhibitor resistance in Hepatitis C virus. Sci. Transl. Med. 2, 30ra32 (2010).","journal-title":"Sci. Transl. Med."},{"key":"51335_CR19","doi-asserted-by":"publisher","first-page":"29621","DOI":"10.1074\/jbc.270.50.29621","volume":"270","author":"T Ridky","year":"1995","unstructured":"Ridky, T. & Leis, J. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270, 29621\u201329623 (1995).","journal-title":"J. Biol. Chem."},{"key":"51335_CR20","doi-asserted-by":"publisher","first-page":"eabo0718","DOI":"10.1126\/scitranslmed.abo0718","volume":"14","author":"LJ Stevens","year":"2022","unstructured":"Stevens, L. J. et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Sci. Transl. Med. 14, eabo0718 (2022).","journal-title":"Sci. Transl. Med."},{"key":"51335_CR21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41467-022-29104-y","volume":"13","author":"S Gandhi","year":"2022","unstructured":"Gandhi, S. et al. De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report. Nat. Commun. 13, 1547 (2022).","journal-title":"Nat. Commun."},{"key":"51335_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.cmi.2024.01.029","volume":"30","author":"MP Hern\u00e1ndez-Mitre","year":"2024","unstructured":"Hern\u00e1ndez-Mitre, M. P. et al. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: A systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate. Clin. Microbiol. Infect. 30, 743\u2013754 (2024).","journal-title":"Clin. Microbiol. Infect."},{"key":"51335_CR23","doi-asserted-by":"publisher","first-page":"eRW0045","DOI":"10.31744\/einstein_journal\/2022RW0045","volume":"20","author":"VY Moraes","year":"2022","unstructured":"Moraes, V. Y. et al. Hydroxychloroquine for treatment of COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Einstein (Sao Paulo) 20, eRW0045 (2022).","journal-title":"Einstein (Sao Paulo)"},{"key":"51335_CR24","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","volume":"12","author":"C Axfors","year":"2021","unstructured":"Axfors, C. et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat. Commun. 12, 2349 (2021).","journal-title":"Nat. Commun."},{"key":"51335_CR25","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","volume":"383","author":"RECOVERY Collaborative Group","year":"2020","unstructured":"RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with covid-19. N. Engl. J. Med. 383, 2030\u20132040 (2020).","journal-title":"N. Engl. J. Med."},{"key":"51335_CR26","first-page":"CD013587","volume":"2","author":"B Singh","year":"2021","unstructured":"Singh, B., Ryan, H., Kredo, T., Chaplin, M. & Fletcher, T. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst. Rev. 2, CD013587 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"51335_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12985-023-01971-x","volume":"20","author":"C Zhang","year":"2023","unstructured":"Zhang, C. et al. Bafilomycin A1 inhibits SARS-CoV-2 infection in a human lung xenograft mouse model. Virol. J. 20, 18 (2023).","journal-title":"Virol. J."},{"key":"51335_CR28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1749-6632.1997.tb52329.x","volume":"834","author":"DJ Keeling","year":"1997","unstructured":"Keeling, D. J., Hersl\u00f6f, M., Ryberg, B., Sj\u00f6gren, S. & S\u00f6lvell, L. Vacuolar H(+)-ATPases. Targets for drug discovery?. Ann. N. Y. Acad. Sci. 834, 600\u2013608 (1997).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"51335_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15562-9","volume":"11","author":"X Ou","year":"2020","unstructured":"Ou, X. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 11, 1620 (2020).","journal-title":"Nat. Commun."},{"key":"51335_CR30","doi-asserted-by":"publisher","first-page":"20803","DOI":"10.1073\/pnas.2007837117","volume":"117","author":"Y-L Kang","year":"2020","unstructured":"Kang, Y.-L. et al. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc. Natl. Acad. Sci. U. S. A. 117, 20803\u201320813 (2020).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"51335_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.virol.2022.05.004","volume":"572","author":"P Kumar","year":"2022","unstructured":"Kumar, P. et al. Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. Virology 572, 64\u201371 (2022).","journal-title":"Virology"},{"key":"51335_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00144-23","volume":"97","author":"P Kettunen","year":"2023","unstructured":"Kettunen, P. et al. SARS-CoV-2 infection of human neurons is TMPRSS2 independent, requires endosomal cell entry, and can be blocked by inhibitors of host phosphoinositol-5 kinase. J. Virol. 97, e0014423 (2023).","journal-title":"J. Virol."},{"key":"51335_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03766-2","volume":"5","author":"J Logue","year":"2022","unstructured":"Logue, J. et al. PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19. Commun. Biol. 5, 808 (2022).","journal-title":"Commun. Biol."},{"key":"51335_CR34","unstructured":"OrphAI Therapeutics. A Study of LAM-002A for the Prevention of Progression of COVID-19. (2023). https:\/\/clinicaltrials.gov\/study\/NCT04446377"},{"key":"51335_CR35","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.1172\/JCI87148","volume":"126","author":"SM Kim","year":"2016","unstructured":"Kim, S. M. et al. Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways. J. Clin. Invest. 126, 4088\u20134102 (2016).","journal-title":"J. Clin. Invest."},{"key":"51335_CR36","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1093\/nar\/gkad023","volume":"51","author":"BT Finicle","year":"2023","unstructured":"Finicle, B. T. et al. Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics. Nucleic Acids Res. 51, 1583\u20131599 (2023).","journal-title":"Nucleic Acids Res."},{"key":"51335_CR37","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202013086","volume":"13","author":"V Jayashankar","year":"2021","unstructured":"Jayashankar, V. et al. Drug-like sphingolipid SH-BC-893 opposes ceramide-induced mitochondrial fission and corrects diet-induced obesity. EMBO Mol. Med. 13, e13086 (2021).","journal-title":"EMBO Mol. Med."},{"key":"51335_CR38","doi-asserted-by":"publisher","first-page":"10382","DOI":"10.1128\/JVI.00747-06","volume":"80","author":"N De Albuquerque","year":"2006","unstructured":"De Albuquerque, N. et al. Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A\/J mice. J. Virol. 80, 10382\u201310394 (2006).","journal-title":"J. Virol."},{"key":"51335_CR39","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1021\/acschembio.5b00761","volume":"11","author":"B Chen","year":"2016","unstructured":"Chen, B. et al. Azacyclic FTY720 analogues that limit nutrient transporter expression but lack S1P receptor activity and negative chronotropic effects offer a novel and effective strategy to kill cancer cells in vivo. ACS Chem. Biol. 11, 409\u2013414 (2016).","journal-title":"ACS Chem. Biol."},{"key":"51335_CR40","doi-asserted-by":"crossref","unstructured":"Finicle, B. T. et al. Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6. J. Cell. Sci. 131, (2018).","DOI":"10.1242\/jcs.213314"},{"key":"51335_CR41","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/22221751.2022.2059403","volume":"11","author":"Y-Q Zhou","year":"2022","unstructured":"Zhou, Y.-Q. et al. SARS-CoV-2 pseudovirus enters the host cells through spike protein-CD147 in an Arf6-dependent manner. Emerg. Microbes Infect. 11, 1135\u20131144 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"51335_CR42","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001868","author":"C Mirabelli","year":"2023","unstructured":"Mirabelli, C. et al. ARF6 is a host factor for SARS-CoV-2 infection in vitro. J. Gen. Virol. https:\/\/doi.org\/10.1099\/jgv.0.001868 (2023).","journal-title":"J. Gen. Virol."},{"key":"51335_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01025-8","volume":"7","author":"J Su","year":"2022","unstructured":"Su, J. et al. PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron. Signal Transduct. Target. Ther. 7, 167 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"51335_CR44","first-page":"162","volume":"21","author":"AM Carabelli","year":"2023","unstructured":"Carabelli, A. M. et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat. Rev. Microbiol. 21, 162\u2013177 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"51335_CR45","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1099\/vir.0.81749-0","volume":"87","author":"X Ren","year":"2006","unstructured":"Ren, X. et al. Analysis of ACE2 in polarized epithelial cells: Surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J. Gen. Virol. 87, 1691\u20131695 (2006).","journal-title":"J. Gen. Virol."},{"key":"51335_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","volume":"23","author":"CB Jackson","year":"2021","unstructured":"Jackson, C. B., Farzan, M., Chen, B. & Choe, H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3\u201320 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"51335_CR47","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/1873-3468.12121","volume":"590","author":"EM Selwan","year":"2016","unstructured":"Selwan, E. M., Finicle, B. T., Kim, S. M. & Edinger, A. L. Attacking the supply wagons to starve cancer cells to death. FEBS Lett. 590, 885\u2013907 (2016).","journal-title":"FEBS Lett."},{"key":"51335_CR48","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1600-0854.2009.00894.x","volume":"10","author":"CA Eyster","year":"2009","unstructured":"Eyster, C. A. et al. Discovery of new cargo proteins that enter cells through clathrin-independent endocytosis. Traffic 10, 590\u2013599 (2009).","journal-title":"Traffic"},{"key":"51335_CR49","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280e8 (2020).","journal-title":"Cell"},{"key":"51335_CR50","doi-asserted-by":"publisher","first-page":"e2407437121","DOI":"10.1073\/pnas.2407437121","volume":"121","author":"B Qu","year":"2024","unstructured":"Qu, B. et al. TMPRSS2-mediated SARS-CoV-2 uptake boosts innate immune activation, enhances cytopathology, and drives convergent virus evolution. Proc. Natl. Acad. Sci. USA. 121, e2407437121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"51335_CR51","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-022-04474-x","volume":"603","author":"B Meng","year":"2022","unstructured":"Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706\u2013714 (2022).","journal-title":"Nature"},{"key":"51335_CR52","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161\u20131179 (2022).","journal-title":"Nat. Microbiol."},{"key":"51335_CR53","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","volume":"603","author":"KPY Hui","year":"2022","unstructured":"Hui, K. P. Y. et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature 603, 715\u2013720 (2022).","journal-title":"Nature"},{"key":"51335_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"H Shuai","year":"2022","unstructured":"Shuai, H. et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature 603, 693\u2013699 (2022).","journal-title":"Nature"},{"key":"51335_CR55","doi-asserted-by":"publisher","first-page":"15174","DOI":"10.1074\/jbc.RA120.015249","volume":"295","author":"MJ Edwards","year":"2020","unstructured":"Edwards, M. J. et al. Sphingosine prevents binding of SARS-CoV-2 spike to its cellular receptor ACE2. J. Biol. Chem. 295, 15174\u201315182 (2020).","journal-title":"J. Biol. Chem."},{"key":"51335_CR56","doi-asserted-by":"publisher","first-page":"12231","DOI":"10.1074\/jbc.RA119.007958","volume":"294","author":"Q Yu","year":"2019","unstructured":"Yu, Q. et al. A NAV2729-sensitive mechanism promotes adrenergic smooth muscle contraction and growth of stromal cells in the human prostate. J. Biol. Chem. 294, 12231\u201312249 (2019).","journal-title":"J. Biol. Chem."},{"key":"51335_CR57","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00975-21","volume":"95","author":"AJB Kreutzberger","year":"2021","unstructured":"Kreutzberger, A. J. B. et al. Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease. J. Virol. 95, e0097521 (2021).","journal-title":"J. Virol."},{"key":"51335_CR58","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1038\/s44318-025-00490-5","volume":"44","author":"V Jayashankar","year":"2025","unstructured":"Jayashankar, V. et al. Sphingosine simultaneously inhibits nuclear import and activates PP2A by binding importins and PPP2R1A. EMBO J. 44, 4473\u20134498 (2025).","journal-title":"EMBO J."},{"key":"51335_CR59","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1074\/mcp.RA118.001053","volume":"18","author":"P Kubiniok","year":"2019","unstructured":"Kubiniok, P. et al. Dynamic phosphoproteomics uncovers signaling pathways modulated by anti-oncogenic sphingolipid analogs. Mol. Cell. Proteomics 18, 408\u2013422 (2019).","journal-title":"Mol. Cell. Proteomics"},{"key":"51335_CR60","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1073\/pnas.0505577102","volume":"102","author":"G Simmons","year":"2005","unstructured":"Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U.S.A. 102, 11876\u201311881 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"51335_CR61","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1074\/jbc.M508381200","volume":"281","author":"I-C Huang","year":"2006","unstructured":"Huang, I.-C. et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J. Biol. Chem. 281, 3198\u20133203 (2006).","journal-title":"J. Biol. Chem."},{"key":"51335_CR62","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/tra.12199","volume":"15","author":"GHE Kim","year":"2014","unstructured":"Kim, G. H. E., Dayam, R. M., Prashar, A., Terebiznik, M. & Botelho, R. J. PIKfyve inhibition interferes with phagosome and endosome maturation in macrophages. Traffic 15, 1143\u20131163 (2014).","journal-title":"Traffic"},{"key":"51335_CR63","doi-asserted-by":"publisher","first-page":"e0005540","DOI":"10.1371\/journal.pntd.0005540","volume":"11","author":"EA Nelson","year":"2017","unstructured":"Nelson, E. A. et al. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Negl. Trop. Dis. 11, e0005540 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"51335_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF01309300","volume":"81","author":"SW Barthold","year":"1984","unstructured":"Barthold, S. W. & Smith, A. L. Mouse hepatitis virus strain\u2013related patterns of tissue tropism in suckling mice. Arch. Virol. 81, 103\u2013112 (1984).","journal-title":"Arch. Virol."},{"key":"51335_CR65","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41586-020-2787-6","volume":"586","author":"C Mu\u00f1oz-Fontela","year":"2020","unstructured":"Mu\u00f1oz-Fontela, C. et al. Animal models for COVID-19. Nature 586, 509\u2013515 (2020).","journal-title":"Nature"},{"key":"51335_CR66","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","volume":"183","author":"SR Leist","year":"2020","unstructured":"Leist, S. R. et al. A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice. Cell 183, 1070-1085e12 (2020).","journal-title":"Cell"},{"key":"51335_CR67","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01564-16","author":"JM Phillips","year":"2017","unstructured":"Phillips, J. M., Gallagher, T. & Weiss, S. R. Neurovirulent murine coronavirus JHM.SD uses cellular zinc metalloproteases for virus entry and cell-cell fusion. J. Virol. https:\/\/doi.org\/10.1128\/JVI.01564-16 (2017).","journal-title":"J. Virol."},{"key":"51335_CR68","doi-asserted-by":"publisher","first-page":"9278","DOI":"10.1128\/JVI.00330-10","volume":"84","author":"JL Leibowitz","year":"2010","unstructured":"Leibowitz, J. L. et al. Genetic determinants of mouse hepatitis virus strain 1 pneumovirulence. J. Virol. 84, 9278\u20139291 (2010).","journal-title":"J. Virol."},{"key":"51335_CR69","doi-asserted-by":"publisher","first-page":"L232","DOI":"10.1152\/ajplung.00324.2023","volume":"327","author":"A Murthy","year":"2024","unstructured":"Murthy, A. et al. Activation of alveolar epithelial ER stress by \u03b2-coronavirus infection disrupts surfactant homeostasis in mice: Implications for COVID-19 respiratory failure. Am. J. Physiol. Lung Cell. Mol. Physiol. 327, L232\u2013L249 (2024).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"51335_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/cpz1.896","volume":"3","author":"AD Masciarella","year":"2023","unstructured":"Masciarella, A. D. et al. A mouse model of MHV-1 virus infection for study of acute and Long COVID infection. Curr. Protoc. 3, e896 (2023).","journal-title":"Curr. Protoc."},{"key":"51335_CR71","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1099\/jgv.0.000309","volume":"96","author":"SD Dowall","year":"2015","unstructured":"Dowall, S. D. et al. Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. J. Gen. Virol. 96, 3484\u20133492 (2015).","journal-title":"J. Gen. Virol."},{"key":"51335_CR72","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3201\/eid2106.150176","volume":"21","author":"D Falzarano","year":"2015","unstructured":"Falzarano, D. et al. Lack of protection against Ebola virus from chloroquine in mice and hamsters. Emerg. Infect. Dis. 21, 1065\u20131067 (2015).","journal-title":"Emerg. Infect. Dis."},{"key":"51335_CR73","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1038\/s41598-022-08684-1","volume":"12","author":"WS Chan","year":"2022","unstructured":"Chan, W. S. et al. Geographical prevalence of SARS-CoV-2 variants, August 2020 to July 2021. Sci. Rep. 12, 4704 (2022).","journal-title":"Sci. Rep."},{"key":"51335_CR74","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature10348","volume":"477","author":"JE Carette","year":"2011","unstructured":"Carette, J. E. et al. Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature 477, 340\u2013343 (2011).","journal-title":"Nature"},{"key":"51335_CR75","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1126\/science.1110656","volume":"308","author":"K Chandran","year":"2005","unstructured":"Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P. & Cunningham, J. M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308, 1643\u20131645 (2005).","journal-title":"Science"},{"key":"51335_CR76","doi-asserted-by":"crossref","unstructured":"Finch, C. L. et al. Formulation, stability, pharmacokinetic, and modeling studies for tests of synergistic combinations of orally available approved drugs against ebola virus in vivo. Microorganisms. 9 (2021).","DOI":"10.3390\/microorganisms9030566"},{"key":"51335_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.virol.2017.09.028","volume":"513","author":"S Qiu","year":"2018","unstructured":"Qiu, S. et al. Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry. Virology 513, 17\u201328 (2018).","journal-title":"Virology"},{"key":"51335_CR78","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/ibd.21159","volume":"16","author":"BE Sands","year":"2010","unstructured":"Sands, B. E. et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12\/23 inhibitor apilimod mesylate for treatment of active Crohn\u2019s disease. Inflamm. Bowel Dis. 16, 1209\u20131218 (2010).","journal-title":"Inflamm. Bowel Dis."},{"key":"51335_CR79","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/art.34339","volume":"64","author":"S Krausz","year":"2012","unstructured":"Krausz, S. et al. Brief report: A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12\/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum. 64, 1750\u20131755 (2012).","journal-title":"Arthritis Rheum."},{"key":"51335_CR80","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/9780470942390.mo140295","volume":"5","author":"J Goh","year":"2015","unstructured":"Goh, J. & Ladiges, W. Voluntary wheel running in mice. Curr. Protoc. Mouse Biol. 5, 283\u2013290 (2015).","journal-title":"Curr. Protoc. Mouse Biol."},{"key":"51335_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2006159","volume":"16","author":"C H\u00e4ger","year":"2018","unstructured":"H\u00e4ger, C. et al. Running in the wheel: Defining individual severity levels in mice. PLoS Biol. 16, e2006159 (2018).","journal-title":"PLoS Biol."},{"key":"51335_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61431-8","volume":"16","author":"C Zhang","year":"2025","unstructured":"Zhang, C. et al. Host protein ARF1 is a proviral factor for SARS-CoV-2 and a candidate broad-spectrum therapeutic target. Nat. Commun. 16, 6326 (2025).","journal-title":"Nat. Commun."},{"key":"51335_CR83","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2025.2223","volume":"6","author":"JPA Ioannidis","year":"2025","unstructured":"Ioannidis, J. P. A., Pezzullo, A. M., Cristiano, A. & Boccia, S. Global estimates of lives and life-years saved by COVID-19 vaccination during 2020\u20132024. JAMA. Health Forum 6, e252223 (2025).","journal-title":"JAMA. Health Forum"},{"key":"51335_CR84","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202871119","volume":"119","author":"GT Keusch","year":"2022","unstructured":"Keusch, G. T. et al. Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses. Proc. Natl. Acad. Sci. U. S. A. 119, e2202871119 (2022).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"51335_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-62703-128-8_1","volume":"946","author":"CC Uphoff","year":"2013","unstructured":"Uphoff, C. C. & Drexler, H. G. Detection of mycoplasma contaminations. Methods Mol. Biol. 946, 1\u201313 (2013).","journal-title":"Methods Mol. Biol."},{"key":"51335_CR86","doi-asserted-by":"crossref","unstructured":"Leibowitz, J., Kaufman, G. & Liu, P. Coronaviruses: propagation, quantification, storage, and construction of recombinant mouse hepatitis virus. Curr Protoc. Microbiol. Chapter 15, (2011). Unit 15E.1.","DOI":"10.1002\/9780471729259.mc15e01s21"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51335-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51335-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51335-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:02:57Z","timestamp":1783645377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51335-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51335"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51335-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patent application.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21524"}}